Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512293 | 0.80 | CYP1A2 (0.59) | CYP1A2LMNAKDM4EPOLBCASP6 | |
| SCHEMBL219949 | 0.77 | PKM (0.33) | — | |
| SCHEMBL14644333 | 0.73 | KDM4E (0.38) | KDM4EPOLBALDH1A1 | |
| SCHEMBL27110359 | 0.73 | — | — | |
| SCHEMBL17088190 | 0.72 | KCNH2 (0.31) | — | |
| SCHEMBL26828858 | 0.72 | PARP1 (0.30) | — | |
| SCHEMBL12702835 | 0.72 | PDE2A (0.31) | — | |
| SCHEMBL14644341 | 0.70 | — | — | |
| SCHEMBL27109601 | 0.70 | NQO2 (0.40) | CYP1A2KDM4EALDH1A1NQO2 | |
| SCHEMBL14644342 | 0.68 | MET (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023110138-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| WO-2023275337-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275336-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275333-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2021058592-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-20160058894-A1 | RADIOLABELED PDE10A LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2016-03-03 | — | — | US | disclosed |
| US-9138494-B2 | Radiolabeled PDE10A ligands | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2307400-B1 | INHIBITORS OF PI3 KINASE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8415376-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2013-04-09 | — | — | US | disclosed |
| WO-2013007663-A1 | 2-BENZYLSULFANYL[1,3,4]-OXADIAZOLE DERIVATIVES, AND MEDICAL USE THEREOF | Technische Universität Darmstadt (DE) | 2013-01-17 | — | — | WO | disclosed |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. | 2011-04-21 | — | — | US | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | CYP1A2 1890/4885LMNA 2497/4885KDM4E 2316/4885 |
| US-20160058894-A1 | RADIOLABELED PDE10A LIGANDS | PDE10A, PDE3A, PDE5A | CYP1A2 910/4885LMNA 1232/4885KDM4E 4115/4885 |
| US-20110092504-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3R1, PIK3R5 | CYP1A2 3274/4885LMNA 2214/4885KDM4E 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.